IPSEN (IPSEY)
(Delayed Data from OTC)
$33.31 USD
-0.35 (-1.04%)
Updated Jun 7, 2024 12:17 PM ET
4-Sell of 5 4
C Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPSEY 33.31 -0.35(-1.04%)
Will IPSEY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IPSEY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSEY
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
IPSEY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
Other News for IPSEY
Ipsen and Marengo Therapeutics announce second strategic partnership
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
Ipsen appoints Josep Catla as EVP, chief corporate affairs officer
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis